Xilio Therapeutics Overview
- Founded
- 2016
- Status
- Public
- Employees
- 74
- Stock Symbol
- XLO
- Share Price
- $7.11
- (As of Monday Closing)
Xilio Therapeutics General Information
Description
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer.
Contact Information
- 828 Winter Street
- Suite 300
- Waltham, MA 02451
- United States
Xilio Therapeutics Timeline
Xilio Therapeutics Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$7.11 | $8.58 | $7.06 - $27.95 | $236M | 27.5M | 83.1K | -$13.52 |
Xilio Therapeutics Financials Summary
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 583,293 | 583,293 | ||
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (74,301) | (74,301) | (54,154) | (17,071) |
Net Income | (75,800) | (75,800) | (55,219) | (17,311) |
Total Assets | 218,060 | 218,060 | 36,317 | 62,722 |
Total Debt | 20,536 | 20,536 | 21,217 | 18,631 |
Xilio Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Xilio Therapeutics‘s full profile, request access.
Request a free trialXilio Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Xilio Therapeutics‘s full profile, request access.
Request a free trialXilio Therapeutics Comparisons
Industry
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialXilio Therapeutics Competitors (1)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
00000000 000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
Xilio Therapeutics Executive Team (15)
Xilio Therapeutics Board Members (26)
Name | Representing | Role | Since |
---|---|---|---|
Andrew Hack Ph.D | Bain Capital Life Sciences | Board Member | 000 0000 |
Christina Rossi | Self | Board Member | 000 0000 |
Daniel Curran | Takeda Ventures | Board Member | 000 0000 |
Daniel Lynch | Self | Chairman of the Board | 000 0000 |
David Gardner | Rock Springs Capital | Board Member | 000 0000 |
Xilio Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialXilio Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Xilio Therapeutics‘s full profile, request access.
Request a free trial